The still-growing list reflects recent advances in precision medicine that target specific components of the inflammatory cascade that drives psoriasis, including tumor necrosis factor (TNF)-alpha ...

Psoriasis was less likely to progress to psoriatic arthritis (PsA) among patients treated with interleukin-17 (IL-17) or IL-23 inhibitors compared with those receiving tumor necrosis factor (TNF ...

This process leads to increased production of TNF-α by macrophages and activation of the inflammatory response. [24] Diseases such as RA, CD, psoriasis, PsA and AS present similar characteristics ...

Adalimumab was the third TNF inhibitor to be approved for psoriasis, but has been gaining momentum in the market against etanercept, owing to superior efficacy data from clinical trials (Psoriasis ...

The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.

Methotrexate is a common treatment option for psoriasis. Newer medications ... These drugs inhibit the production of tumor necrosis factor (TNF), an inflammation-causing substance in the blood.

Cardiac Risks With Newer Psoriasis Meds Match TNF Inhibitors A study of biologic-naive patients with psoriasis or PsA found that IL-17, IL-12/23, and IL-23 inhibitors have cardiovascular and ...

Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Some 25% of ...